Cavero I, Dennis T, Lefèvre-Borg F, Perrot P, Roach A G, Scatton B
Br J Pharmacol. 1979 Oct;67(2):283-92. doi: 10.1111/j.1476-5381.1979.tb08678.x.
1 In spinal dogs, continuous electrical stimulation of the cardioaccelerator nerve produced a transient rise in aortic blood pressure and a sustained increase in both heart rate and coronary sinus blood flow. The latter effects were accompanied by a significant elevation in the coronary sinus plasma noradrenaline concentration without significant changes in the levels of dopamine and adrenaline. The concentrations of the three catecholamines in thoracic aorta plasma were not significantly changed by cardioaccelerator nerve stimulation.2 Clonidine (20 mug/kg, i.v.), given during cardioaccelerator nerve stimulation, increased both mean aortic blood pressure and coronary sinus blood flow and decreased heart rate and coronary sinus venous plasma noradrenaline overflow.3 Phentolamine (0.3 mg/kg, i.v.) completely antagonized these effects of clonidine. Prazosin (0.3 mg/kg, i.v.) inhibited by only 43 and 38% the respective reductions in heart rate and noradrenaline overflow elicited by clonidine.4 On termination of cardioaccelerator stimulation (about 10 min after either prazosin or phentolamine), heart rate and coronary sinus noradrenaline overflow returned to control prestimulation levels.5 Phentolamine or prazosin, administered alone during stimulation of the cardioaccelerator nerve, increased heart rate and noradrenaline overflow into the coronary sinus plasma. However, intravenous phentolamine and prazosin, in contrast to desipramine (0.3 mg/kg, i.v.) or tyramine (1.0 mg, i.a.), failed to change the tachycardia resulting from the local administration of noradrenaline into the sinus node artery (i.a.).6 These results show that in spinal dogs the clonidine-induced reduction in heart rate (elevated by electrical stimulation of the cardioaccelerator nerve) is accompanied by a fall in the quantity of noradrenaline overflowing into the coronary sinus plasma. The latter effect is presumably the result of an action of clonidine on cardiac presynaptic alpha-adrenoceptors, the activation of which is followed by a reduction in the release of noradrenaline per nerve impulse. Phentolamine and prazosin are both antagonists of cardiac presynaptic alpha-adrenoceptors in spinal dogs, as suggested by their action against clonidine and by their positive chronotropic effect when administered during stimulation of the cardioaccelerator nerve.
在脊髓麻醉犬中,持续电刺激心脏加速神经可使主动脉血压短暂升高,心率和冠状窦血流量持续增加。后一种效应伴随着冠状窦血浆去甲肾上腺素浓度显著升高,而多巴胺和肾上腺素水平无明显变化。心脏加速神经刺激未使胸主动脉血浆中三种儿茶酚胺的浓度发生显著改变。
在心脏加速神经刺激期间静脉注射可乐定(20μg/kg),可使平均主动脉血压和冠状窦血流量增加,心率和冠状窦静脉血浆去甲肾上腺素溢出量减少。
酚妥拉明(0.3mg/kg,静脉注射)完全拮抗了可乐定的这些效应。哌唑嗪(0.3mg/kg,静脉注射)仅分别抑制了可乐定引起的心率降低和去甲肾上腺素溢出减少的43%和38%。
在心脏加速刺激终止时(哌唑嗪或酚妥拉明给药后约10分钟),心率和冠状窦去甲肾上腺素溢出量恢复到刺激前的对照水平。
在心脏加速神经刺激期间单独给予酚妥拉明或哌唑嗪,可使心率和去甲肾上腺素向冠状窦血浆中的溢出量增加。然而,与地昔帕明(0.3mg/kg,静脉注射)或酪胺(1.0mg,动脉注射)不同,静脉注射酚妥拉明和哌唑嗪未能改变向窦房结动脉局部注射去甲肾上腺素所引起的心动过速。
这些结果表明,在脊髓麻醉犬中,可乐定引起的心率降低(由心脏加速神经的电刺激所升高)伴随着冠状窦血浆中去甲肾上腺素溢出量的减少。后一种效应可能是可乐定作用于心脏突触前α-肾上腺素能受体的结果,该受体的激活随后导致每个神经冲动去甲肾上腺素释放减少。酚妥拉明和哌唑嗪都是脊髓麻醉犬心脏突触前α-肾上腺素能受体的拮抗剂,这可从它们对可乐定的作用以及在心脏加速神经刺激期间给药时的正性变时效应得到提示。